Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Berubicin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CNS Pharmaceuticals Updates on Berubicin Study in GBM
    CNS Pharmaceuticals Updates on Berubicin Study in GBM

    25 Nov 2024

    // ACCESSWIRE

    https://www.accesswire.com/946585/cns-pharmaceuticals-presents-update-from-ongoing-potentially-pivotal-study-of-berubicin-compared-with-lomustine-in-adult-patients-with-recurrent-gbm-who-grade-iv-after-failure-of-standard-first-line-therapy

    ACCESSWIRE
    25 Nov 2024
    Share Share
    CNS Achieves Completion of Enrollment in Pivotal Study of Berubicin
    CNS Achieves Completion of Enrollment in Pivotal Study of Berubicin

    17 Jan 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=825674&lang=en

    ACCESSWIRE
    17 Jan 2024
    Share Share
    CNS Announces Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
    CNS Announces Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

    18 Dec 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=817849&lang=en

    ACCESSWIRE
    18 Dec 2023
    Share Share
    CNS Pharma Presents Safety Data from Pivotal Study Evaluating Berubicin
    CNS Pharma Presents Safety Data from Pivotal Study Evaluating Berubicin

    22 Nov 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=808204&lang=en

    ACCESSWIRE
    22 Nov 2023
    Share Share
    CNS Pharmaceuticals' Ongoing Potentially Pivotal Study of Berubicin
    CNS Pharmaceuticals' Ongoing Potentially Pivotal Study of Berubicin

    11 Oct 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=791819&lang=en

    ACCESSWIRE
    11 Oct 2023
    Share Share
    CNS Reaches Milestone with Enrollment of 200 Patients in Study of Berubicin
    CNS Reaches Milestone with Enrollment of 200 Patients in Study of Berubicin

    07 Sep 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=781455&lang=en

    ACCESSWIRE
    07 Sep 2023
    Share Share